Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Business alliance4978ReproCELL Incorporated
Alliance partnerTOHO HOLDINGS CO.,LTD.
Details of the alliance
- 1
Discussion and consideration of supply arrangements for medical institutions nationwide and distribution arrangements suited to the characteristics of regenerative medicine products
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionHas a pharmaceutical distribution network
Impact on Business Performance
We currently expect the impact of this matter on the current fiscal year's results to be minor.
Contract Date17 September 2026Alliance start dateAfter obtaining marketing approval (planned)
| Item | Details |
|---|---|
| Name of alliance partner | TOHO HOLDINGS CO.,LTD. |
| Alliance partner's business activities | Has a pharmaceutical distribution network |
| Type of alliance | Business alliance |
| Details of the alliance | Discussion and consideration of supply arrangements for medical institutions nationwide and distribution arrangements suited to the characteristics of regenerative medicine products |
| Contract Date | 17 September 2026 |
| Alliance start date | After obtaining marketing approval (planned) |
| Impact on Business Performance | We currently expect the impact of this matter on the current fiscal year's results to be minor. |
Items this document does not state (16)
Alliance partner's locationAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To achieve a smooth market launch and stable supply to medical institutions nationwide after obtaining marketing approval for "Stemchymal".
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.